Last updated: August 13, 2026
Arbor Pharmaceuticals, LLC v. Lupin Limited, No. 1:20-cv-00922, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Lupin's abbreviated new drug application for a generic version of Katerzia, Arbor's amlodipine besylate oral suspension. Arbor asserted U.S. Patent No. 10,610,542. The case was resolved without a reported claim-construction ruling, infringement trial, or merits judgment. The public docket does not disclose the commercial terms of the parties' resolution. [1][2]
What drug and formulation were at issue in Arbor Pharmaceuticals v. Lupin?
The case concerned Katerzia, an oral suspension containing amlodipine besylate.
Katerzia is a liquid formulation of amlodipine, a dihydropyridine calcium-channel blocker used to treat hypertension and coronary artery disease. Arbor developed the product for patients who have difficulty swallowing conventional tablets, including pediatric and other patients requiring a liquid dosage form. The dispute therefore centered on formulation and product-specific patent rights rather than a new chemical entity patent.
| Item |
Detail |
| Brand |
Katerzia |
| Active ingredient |
Amlodipine besylate |
| Dosage form |
Oral suspension |
| NDA holder |
Arbor Pharmaceuticals, LLC |
| Generic applicant |
Lupin Limited |
| Regulatory pathway |
ANDA under the Hatch-Waxman Act |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:20-cv-00922 |
| Asserted patent |
U.S. Patent No. 10,610,542 |
| Filing year |
2020 |
| Disposition |
Resolved and closed without a reported merits decision |
Katerzia differs from standard amlodipine tablets because the commercial product requires a stable, pharmaceutically acceptable liquid suspension. That distinction created the patent issue: Lupin's proposed product had to be evaluated against claims directed to the composition and formulation of the oral suspension, not merely against the active ingredient amlodipine.
What patent protected Katerzia in the Lupin litigation?
Arbor asserted U.S. Patent No. 10,610,542, which covers an amlodipine oral suspension formulation. The patent was assigned to Arbor Pharmaceuticals and was listed in the FDA Orange Book for Katerzia. [2][3]
The patent estate was narrower than a composition-of-matter estate covering amlodipine itself. Amlodipine is an established generic active ingredient with extensive prior-art exposure. The commercial value of the asserted patent instead depended on whether its formulation claims covered the precise excipient system, suspension characteristics, concentration, and manufacturing parameters used in Katerzia.
What formulation claims mattered?
The principal patent-risk categories were:
- A liquid oral suspension containing amlodipine or amlodipine besylate.
- The relative amounts of active ingredient and excipients.
- Physical stability and uniformity of the suspension.
- Pharmaceutical acceptability for oral administration.
- Product characteristics that distinguish the suspension from conventional amlodipine tablets or extemporaneously prepared liquids.
Formulation patents can be commercially important even when the underlying active ingredient is old. Their enforceability depends on claim scope, support in the specification, predictable formulation science, and the extent to which a generic applicant must reproduce the claimed characteristics to obtain FDA approval.
When did Lupin trigger the Paragraph IV litigation?
Lupin's ANDA filing included a Paragraph IV certification against Arbor's Orange Book-listed patent. A Paragraph IV certification states that the listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. Arbor responded by filing the Delaware action within the statutory 45-day period.
A timely Hatch-Waxman suit ordinarily triggers a 30-month stay of FDA approval unless the court resolves the litigation earlier or an exception applies. The stay protects the brand's patent position while the court evaluates the ANDA-based infringement allegations. [4]
The public case record establishes the existence of ANDA litigation and the asserted patent. It does not provide a reported opinion explaining Lupin's detailed invalidity or noninfringement positions. No published decision from the case provides a construction of the disputed claims.
What was the litigation outcome?
The action did not produce a reported trial decision or final judgment addressing patent validity or infringement. The case was resolved through a docket disposition rather than a published merits opinion.
The public record does not disclose:
- The precise settlement date.
- The agreed generic launch date.
- Whether Lupin received a license before patent expiration.
- Whether the agreement included an authorized generic arrangement.
- Whether the settlement contained volume, supply, or other commercial provisions.
- Whether the Federal Trade Commission challenged the agreement.
The absence of a merits ruling is significant. The litigation did not establish whether U.S. Patent No. 10,610,542 was valid, infringed, or enforceable against Lupin's formulation. It also did not create binding claim-construction precedent for later Katerzia cases.
What is the Orange Book status of Katerzia?
Katerzia's Orange Book protection was based on a formulation patent rather than exclusivity over amlodipine as a molecule.
FDA Orange Book implications included:
| Regulatory issue |
Analysis |
| Listed patent |
U.S. Patent No. 10,610,542 |
| Patent type |
Formulation/composition patent |
| Generic certification |
Lupin filed a Paragraph IV certification |
| 30-month stay |
Potentially applicable after Arbor's timely infringement suit |
| NCE exclusivity |
Not the principal protection at issue |
| Pediatric exclusivity |
No case-specific public record establishes that pediatric exclusivity controlled the dispute |
| Biosimilar pathway |
Not applicable because Katerzia is a small-molecule drug |
| Generic approval |
Depended on the ANDA, patent certification, and litigation outcome |
The Orange Book listing did not prevent other companies from developing different amlodipine dosage forms. It created a litigation barrier for an ANDA product that allegedly fell within the listed patent claims.
When does Katerzia lose patent exclusivity?
The asserted patent had an expiration date in the mid-2030s, with Orange Book records identifying a 2035 patent-expiration period for the listed Katerzia formulation patent. [3]
The commercial exclusivity analysis must distinguish three dates:
- The patent expiration date.
- The end of any applicable regulatory exclusivity.
- The date a generic applicant obtains FDA approval.
A patent expiration date does not guarantee immediate generic launch. FDA approval, manufacturing readiness, supply arrangements, pediatric labeling, injunctions, and settlement restrictions can affect market entry. Conversely, a generic may launch before patent expiration if it obtains a license, wins the litigation, or enters at risk.
Because the case ended without a public merits ruling and the settlement terms were not publicly disclosed, the docket does not establish Lupin's authorized launch date.
How strong was Arbor's Katerzia patent estate?
Arbor's estate had commercial value but was narrower than the estate surrounding a new chemical entity.
Strengths
The patent's strongest characteristics were likely:
- Product-specific coverage of an oral amlodipine suspension.
- Orange Book listing and the ability to trigger a Hatch-Waxman stay.
- Potential difficulty designing around the claimed liquid formulation while maintaining equivalent pharmaceutical performance.
- A regulatory pathway requiring Lupin to identify its proposed product and certification position.
Weaknesses
The principal weaknesses were:
- Amlodipine was already widely available as a generic tablet.
- Liquid formulation patents are exposed to obviousness challenges based on known suspension technology.
- Claim scope may be limited to particular excipients or concentration ranges.
- A generic applicant can attempt a design-around using a different vehicle, preservative, suspending agent, pH system, or manufacturing process.
- The case generated no reported decision confirming validity or infringement.
The patent therefore represented a meaningful barrier to a direct Katerzia copy, but not a broad barrier to all liquid amlodipine products.
What generic entry risks existed for Katerzia?
The primary risk was a direct generic oral suspension with an equivalent active ingredient and sufficiently similar formulation. Lupin's ANDA filing showed that a major generic manufacturer considered the product commercially viable despite the listed patent.
Potential entry scenarios included:
| Scenario |
Effect on Arbor |
| Patent upheld and infringed |
Lupin would face delayed approval or a launch restriction until expiration or settlement license |
| Patent invalidated |
Lupin could pursue approval and potentially launch before the listed expiration |
| Noninfringement finding |
A noninfringing Lupin suspension could enter without infringing the asserted patent |
| Licensed entry |
Lupin could launch on a negotiated date under undisclosed settlement terms |
| Design-around |
Lupin or another applicant could develop a different liquid formulation |
| At-risk launch |
Lupin could launch before patent expiry while accepting potential damages and injunction exposure |
The settlement disposition reduced near-term litigation uncertainty but did not eliminate longer-term formulation competition. Other generic applicants could independently challenge the patent or avoid it through a different formulation.
Which companies were challenging Arbor's Katerzia position?
The identified defendant in this action was Lupin Limited. The public record for No. 1:20-cv-00922 does not establish a broader field of named challengers in the same case.
Potential competitive pressure also came from:
- Generic manufacturers developing amlodipine oral liquids.
- Compounding pharmacies producing extemporaneous amlodipine suspensions.
- Tablet manufacturers competing for the broader amlodipine market.
- Other sponsors developing pediatric-friendly antihypertensive formulations.
A competitor did not need to copy Katerzia exactly to challenge Arbor's commercial position. A distinct formulation could avoid the asserted patent while competing for the same patients and prescribers.
Did the case involve biosimilars or method-of-use patents?
No. The litigation involved a small-molecule drug, not a biologic. Biosimilar approval under the Biologics Price Competition and Innovation Act was irrelevant.
The identified dispute was formulation-focused. The public case record does not show that Arbor asserted a separate method-of-use patent involving a new therapeutic indication. The value of the patent was tied to the oral suspension product and its pharmaceutical composition.
What revenue exposure did the Lupin case create?
The case threatened Arbor's revenue from Katerzia's branded oral suspension, not the entire U.S. amlodipine market.
Revenue exposure depended on:
- Katerzia's share of liquid amlodipine prescriptions.
- The number of patients requiring a liquid dosage form.
- Lupin's potential launch timing.
- Generic price discounting.
- Pharmacy substitution and payer coverage.
- The availability of compounded alternatives.
- Arbor's ability to maintain product differentiation.
No reliable public source in the case record provides Katerzia-specific revenue or a quantified valuation of the Lupin challenge. The commercial risk was therefore more concentrated than the risk associated with a blockbuster tablet product, but it could still affect pricing, formulary access, and the value of Arbor's pediatric and dysphagia-focused product franchise.
What does the case mean for pharmaceutical patent strategy?
Arbor Pharmaceuticals v. Lupin illustrates the value and limits of formulation patents in Hatch-Waxman litigation.
A formulation patent can delay a direct generic product even when the active ingredient has been generic for years. The patent must still withstand invalidity and noninfringement attacks based on prior art and design-around options. Orange Book listing creates procedural leverage, but listing alone does not establish patent validity.
For brand companies, the case supports filing layered claims covering composition, concentration, excipient ranges, stability, dosage form, and manufacturing methods. For generic companies, the principal defenses are claim construction, obviousness, lack of infringement, and development of a formulation outside the asserted limitations.
Key Takeaways
- Arbor sued Lupin in Delaware over an ANDA for a generic version of Katerzia.
- Katerzia is an amlodipine besylate oral suspension.
- Arbor asserted U.S. Patent No. 10,610,542, an Orange Book-listed formulation patent.
- Lupin's Paragraph IV certification triggered Hatch-Waxman litigation.
- The case ended without a reported merits decision or public claim-construction ruling.
- Public records do not disclose the settlement's launch date or commercial terms.
- The patent estate protected a specific liquid formulation, not amlodipine generally.
- Biosimilar risk was irrelevant because amlodipine is a small-molecule drug.
- Generic entry could occur through settlement, patent expiration, invalidity, noninfringement, or a design-around formulation.
FAQs
Was Arbor Pharmaceuticals v. Lupin a patent infringement case?
Yes. It was a Hatch-Waxman patent infringement action based on Lupin's Paragraph IV certification concerning an ANDA for generic Katerzia.
What is the main patent number in the Arbor v. Lupin case?
The principal identified patent was U.S. Patent No. 10,610,542, directed to an amlodipine oral suspension formulation.
Did Arbor win the Katerzia patent case?
The case did not produce a reported merits judgment. The public docket reflects resolution and closure without a published decision holding that the patent was valid and infringed.
Was Lupin allowed to launch generic Katerzia?
The public docket does not disclose the settlement's precise launch terms. It does not establish an authorized launch date.
Can another company design around Arbor's Katerzia patent?
Potentially. A competitor could seek a noninfringing formulation using different excipients, concentration ranges, suspension technology, or manufacturing parameters. Whether a specific product avoids infringement would depend on the patent claims and the product's formulation.
References
-
U.S. District Court for the District of Delaware. (2020). Arbor Pharmaceuticals, LLC v. Lupin Limited, No. 1:20-cv-00922, docket filings and disposition.
-
U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,610,542, pharmaceutical composition comprising amlodipine.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book, Katerzia patent listings.
-
Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
